X

Trial Profile

A study of Coversin for the treatment of bullous pemphigoid in patients who are refractory to oral steroids

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nomacopan (Primary)
Indications Bullous pemphigoid
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Aug 2022 Status changed from planning to discontinued, according to an Akari Therapeutics media release.
12 Sep 2018 According to an Akari Therapeutics media release, the company anticipates data from this trial in first quarter of 2019.
21 Mar 2018 According to an Akari Therapeutics media release, the company expects to commence this study in first Half of 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com